Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-20

Clinical Trial Update: A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating rivaroxaban for early discharge of low-risk pulmonary embolism patients from the emergency department, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Pulmonary Embolism | Phase 4 | Status: COMPLETED | Results posted: 2018-04-20